Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for DIVISLAB
Revenue projections for DIVISLAB

Investors are expected to be cautious with Divi's Laboratories Limited, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 6.943000
forwardPE 48.640644
debtToEquity 0.027000
earningsGrowth 0.231000
revenueGrowth 0.122000
grossMargins 0.602030
operatingMargins 0.302900
trailingEps 82.680000
forwardEps 56.300000

DIVISLAB's current ratio, being 6.943, demonstrates that the company has the liquidity necessary to service its short-term debt. With strong cash reserves and current assets, DIVISLAB is well-equipped to meet its immediate financial obligations without any difficulties.
DIVISLAB's positive earnings and revenue growth indicate that the company is well-positioned for business expansion. This growth suggests a strong financial trajectory, with DIVISLAB expected to continue increasing its profits and revenue in the coming periods.
DIVISLAB's positive gross and operating margins suggest the company is performing profitably. These margins reflect efficient cost management and strong revenue generation, signaling healthy financial performance and operational effectiveness.
With DIVISLAB's forward EPS lower than its trailing EPS, the company is expected to experience a drop in profitability. This suggests a potential slowdown in financial performance compared to the previous year.

Price projections:

Price projections for DIVISLAB
Price projections for DIVISLAB

Price projections for DIVISLAB have consistently been revised upward, indicating positive sentiment toward the company. This gradual adjustment reflects growing confidence in DIVISLAB's future potential and financial outlook among analysts.

Insider Transactions:

Insider Transactions for DIVISLAB
Insider Transactions for DIVISLAB


DIVISLAB saw 25 transactions in which shares were sold with market price at 5552.47203125.There were 2 purchases of Divi's Laboratories Limited stock, with market price of 5854.875.The higher volume of buys compared to sells near current DIVISLAB price levels may suggest optimism among investors. This could point to a favorable market outlook, as more people are willing to invest at these prices, anticipating potential future growth or strong performance.

Recommendation changes over time:

Recommendations trend for DIVISLAB
Recommendations trend for DIVISLAB


A recent sell bias for DIVISLAB from analysts suggests caution for investors. However, decisions should be grounded in a diverse set of market indicators, ensuring that a wider perspective is considered before making any moves regarding the stock's performance and potential risks.